Peter Lawson's Stock Ratings

Barclays Analyst

Peter Lawson is an analyst at Barclays. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-7.26%

Smart Score

46.5%

Overall Average Return Percentile

23rd

Number of Ratings

59
Buy NowGet Alert
05/10/2024MGNXBuy Now
Macrogenics
$5.04178.05%$25 → $14MaintainsOverweightGet Alert
05/10/2024RLAYBuy Now
Relay Therapeutics
$6.50130.77%$15 → $15UpgradeEqual-Weight → OverweightGet Alert
05/03/2024BPMCBuy Now
Blueprint Medicines
$107.00-29.91%$70 → $75MaintainsEqual-WeightGet Alert
04/30/2024DCPHBuy Now
Deciphera Pharmaceuticals
$25.462.12%$9 → $26UpgradeUnderweight → Equal-WeightGet Alert
04/11/2024EXELBuy Now
Exelixis
$21.0418.82%$25 → $25DowngradeOverweight → Equal-WeightGet Alert
03/08/2024MGNXBuy Now
Macrogenics
$5.04396.52%$23 → $25MaintainsOverweightGet Alert
03/07/2024TCRXBuy Now
TScan Therapeutics
$8.891.24%$7 → $9MaintainsOverweightGet Alert
02/29/2024ARVNBuy Now
Arvinas
$31.9587.79%$26 → $60MaintainsOverweightGet Alert
02/29/2024IOVABuy Now
Iovance Biotherapeutics
$10.38111.93%$18 → $22MaintainsOverweightGet Alert
02/29/2024MGNXBuy Now
Macrogenics
$5.04356.8%$12 → $23MaintainsOverweightGet Alert
02/29/2024SWTXBuy Now
SpringWorks Therapeutics
$44.9540.16%$47 → $63MaintainsOverweightGet Alert
02/27/2024FATEBuy Now
Fate Therapeutics
$4.07145.7%$6 → $10MaintainsOverweightGet Alert
02/13/2024BPMCBuy Now
Blueprint Medicines
$107.00-34.58%$58 → $70MaintainsEqual-WeightGet Alert
01/30/2024EXELBuy Now
Exelixis
$21.0418.82%$24 → $25MaintainsOverweightGet Alert
01/25/2024SWTXBuy Now
SpringWorks Therapeutics
$44.954.56%$41 → $47MaintainsOverweightGet Alert
12/06/2023REPLBuy Now
Replimune Group
$6.7792.02%$50 → $13MaintainsOverweightGet Alert
12/04/2023IMGNBuy Now
Immunogen
——$27 → $31DowngradeOverweight → Equal-WeightGet Alert
12/01/2023IMGNBuy Now
Immunogen
———DowngradeOverweight → Equal-WeightGet Alert
10/27/2023BPMCBuy Now
Blueprint Medicines
$107.00-45.79%$46 → $58MaintainsEqual-WeightGet Alert
10/24/2023ARVNBuy Now
Arvinas
$31.95-18.62%$39 → $26MaintainsOverweightGet Alert
10/17/2023EXAIBuy Now
Exscientia
$5.0398.81%$12 → $10MaintainsOverweightGet Alert
09/18/2023IOVABuy Now
Iovance Biotherapeutics
$10.3873.4%$40 → $18MaintainsOverweightGet Alert
08/10/2023FATEBuy Now
Fate Therapeutics
$4.0747.42%$12 → $6MaintainsOverweightGet Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.18-15.25%$2 → $1MaintainsUnderweightGet Alert
08/09/2023ARVNBuy Now
Arvinas
$31.9522.07%$70 → $39MaintainsOverweightGet Alert
08/04/2023PRLDBuy Now
Prelude Therapeutics
$4.2118.76%$7 → $5MaintainsEqual-WeightGet Alert
08/03/2023EXELBuy Now
Exelixis
$21.0414.07%$25 → $24MaintainsOverweightGet Alert
08/02/2023IMGNBuy Now
Immunogen
——$20 → $27MaintainsOverweightGet Alert
07/26/2023SNDXBuy Now
Syndax Pharmaceuticals
$20.6065.05%$31 → $34MaintainsOverweightGet Alert
06/12/2023IMGNBuy Now
Immunogen
——$9 → $20MaintainsOverweightGet Alert